| abstract |
The present invention relates to a method of treating cancer and pre-cancerous syndromes in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering: (i) an EZH2 inhibitor selected from: N -[4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1 S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1 H -indole-4-carboxamide, or a pharmaceutically acceptable salt thereof; 1-(1-methylethyl)- N -[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pryidinyl)methyl]-6-[2- (4-methyl-1-piperazinyl)-4-pyridinyl]-1 H -indazole-4-carboxamide, or a pharmaceutically acceptable salt thereof; and N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetahydro-2 H -pyran-4-yl)amino)-4-mehtyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide, or a pharmaceutically acceptable salt thereof; and (ii) a Bcl-2 inhibitor, to a human in need thereof. |